Promising Results With Trastuzumab Deruxtecan in Early HER2+ Breast Cancer

Researchers tested a novel antibody-drug conjugate known as trastuzumab deruxtecan in an expansion cohort of a phase I study of patients with advanced HER2+ breast cancer previously treated with trastuzumab emtansine.

Source: CancerNetwork - May 15, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news